Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Stanley Medical Research Institute
• Treatments: Pravastatin

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder

• Male and female subjects; age 18-65 years inclusive

• Ability to provide informed consent

• No psychiatric hospitalization in the last 30 days prior to randomization

• PANSS score at study entry between 80 and 120 inclusive, OR those who continue to experience some residual positive and/or negative symptoms and are not at their baseline level of functioning.

• Current psychiatric medications stable for at least 30 days

• Currently receiving only one antipsychotic medication

• Female subjects of child-bearing age must use an acceptable method of birth control

Exclusion Criteria:

• Active, uncontrolled, or chronic liver disease

• Heart failure

• Current alcohol abuse or dependence

• Female subjects who are pregnant, lactating or plan to become pregnant during the study period

• History of allergic reaction with any statin in the past

• Kidney disorder or other evidence of renal dysfunction

• Uncontrolled diabetes

• Untreated hyperlipidemia

• Concurrently receiving treatment with cyclosporine, gemfibrozil, clofibrate, fenofibrate, niacin, macrolide antibiotics, erythromycin, HIV protease inhibitors, nefazodone, or verapamil